Gene Expression News and Research

RSS

Gene Expression is the process by which a gene gets turned on in a cell to make RNA and proteins. Gene expression may be measured by looking at the RNA, or the protein made from the RNA, or what the protein does in a cell.

p53 gene blocks EMT essential to cancer metastasis

Like a bounty hunter returning escapees to custody, a cancer-fighting gene converts organ cells that change into highly mobile stem cells back to their original, stationary state, researchers report online at Nature Cell Biology.

28 Feb 2011

Affymetrix introduces new GeneChip miRNA 2.0 Array

Affymetrix, Inc. today launched the GeneChip miRNA 2.0 Array. This enhanced version of its best-in-class microRNA interrogation solution will support the research community's pursuit of personalized medicine by accelerating the identification of biomarkers and gene expression signatures associated with disease.

28 Feb 2011

New findings disclose mechanisms that control Rb2/p130 gene expression in lung cancer cells

Despite innumerable studies on lung cancer, many aspects of the disease have yet to be understood, including the role played by the retinoblastoma-related protein Rb2/p130 in the evolution of the disease.

27 Feb 2011

New study discloses mechanism controlling Rb2/p130 gene expression in lung cancer cells

25 Feb 2011

More than one way to silence gene activity

There's more than one way to silence gene activity, according to a Michigan State University researcher.

25 Feb 2011

Study: AEG-1 expression predicts erlotinib treatment response in patients with EGFR-mutant lung cancer

Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.

25 Feb 2011

Collision of fast and slow protein-trains cause major DNA derailment

Scientists have published results that will forever change the way researchers view the interplay between gene expression, DNA replication and the prevention of DNA damage.

25 Feb 2011

Progeria-derived iPS cells may treat aging-related disease in children

The current pace of population aging is without parallel in human history but surprisingly little is known about the human aging process, because lifespans of eight decades or more make it difficult to study. Now, researchers at the Salk Institute for Biological Studies have replicated premature aging in the lab, allowing them to study aging-related disease in a dish.

24 Feb 2011

New study suggests variation in PCLO gene can contribute to risk of bipolar disorder

Understanding the genetics of bipolar disorder could lead to new treatments, but identifying specific genetic variations associated with this disorder has been challenging.

24 Feb 2011

FDA clears Agendia's breast cancer recurrence assay

Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration clearance for MammaPrint, its widely used breast cancer recurrence assay.

23 Feb 2011

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.

23 Feb 2011

NanoString launches fixed-panel assay product for human molecular karyotyping

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the first fixed-panel assay product to be developed on its Copy Number Variation detection platform - the nCounter Human Karyotype Panel.

From NanoString Technologies 22 Feb 2011

Experimental vaccine appears to protect against pneumonia

Researchers at Albert Einstein College of Medicine of Yeshiva University have developed an experimental vaccine that appears to protect against an increasingly common and particularly deadly form of pneumococcal pneumonia. Details of the new vaccine, which was tested in an animal model, are reported in a paper published today in the Journal of Infectious Diseases.

22 Feb 2011

DiaGenic fourth quarter operating revenue increases to NOK 1,078 thousand

DiaGenic has significantly altered its business strategy during 2010 to leverage more effectively its commercial potential, and strengths in Intellectual Property (IP). The Company has made significant progress in its business activities towards big pharma since implementation of the new strategy. DiaGenic is well positioned as a multimodal partner with large pharma and imaging companies.

18 Feb 2011

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

miRagen Therapeutics, Inc., a privately-held biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's compound MGN-4893 for the treatment of polycythemia vera, a myeloproliferative disease characterized by an overabundance of blood cells and platelets in the body.

18 Feb 2011

Benitec strengthens patent position in RNAi

Benitec Limited (ASX: BLT), (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, is pleased to announce that the United States Patent and Trademark Office (USPTO) has today indicated that it is issuing the Re-examination Certificate, the formal final step in the USPTO’s confirmation of patentability of claims in the key ‘099 Graham Patent [US Patent No. 6,573,099] "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene", the wide-ranging platform technology patent covering the use of expressed RNA interference (RNAi) in human therapeutic applications.

17 Feb 2011

Researchers find blue-green algae may be responsible for producing estrogen-like compound in water

University of Tennessee, Knoxville, researchers have found that blue-green algae may be responsible for producing an estrogen-like compound in the environment which could disrupt the normal activity of reproductive hormones and adversely affect fish, plants and human health.

17 Feb 2011

Unrecognized substances released by algae blooms may act as endocrine disruptors

Scientists are reporting for the first time that previously unrecognized substances released by algae blooms have the potential to act as endocrine disruptors, which can interfere with the normal activity of reproductive hormones. The effect is not caused by microcystin toxins, long recognized as potentially harmful to humans and aquatic animals, but as yet unidentified substances.

17 Feb 2011

Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

Genomic Health, Inc. today announced the presentation of two studies at the American Society of Clinical Oncology® (ASCO®) Genitourinary (GU) Cancer Symposium, including complete results from its prostate cancer gene identification study, which identified 295 genes strongly associated with clinical recurrence following radical prostatectomy with great consistency across multiple tumor samples examined in each patient.

17 Feb 2011

Molecular explanation to higher tendency for autism among males

George Washington University researcher, Dr. Valerie Hu, Professor of Biochemistry and Molecular Biology, and her team at the School of Medicine and Health Sciences, have found that male and female sex hormones regulate expression of an important gene in neuronal cell culture through a mechanism that could explain not only higher levels of testosterone observed in some individuals with autism, but also why males have a higher incidence of autism than females.

17 Feb 2011

Gene Expression News and Research

Further Reading

p53 gene blocks EMT essential to cancer metastasis

Affymetrix introduces new GeneChip miRNA 2.0 Array

New findings disclose mechanisms that control Rb2/p130 gene expression in lung cancer cells

New study discloses mechanism controlling Rb2/p130 gene expression in lung cancer cells

More than one way to silence gene activity

Study: AEG-1 expression predicts erlotinib treatment response in patients with EGFR-mutant lung cancer

Collision of fast and slow protein-trains cause major DNA derailment

Progeria-derived iPS cells may treat aging-related disease in children

New study suggests variation in PCLO gene can contribute to risk of bipolar disorder

FDA clears Agendia's breast cancer recurrence assay

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

NanoString launches fixed-panel assay product for human molecular karyotyping

Experimental vaccine appears to protect against pneumonia

DiaGenic fourth quarter operating revenue increases to NOK 1,078 thousand

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

Benitec strengthens patent position in RNAi

Researchers find blue-green algae may be responsible for producing estrogen-like compound in water

Unrecognized substances released by algae blooms may act as endocrine disruptors

Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

Molecular explanation to higher tendency for autism among males

Industry Focus eBook - Biotechnology (4th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®